



## MTTI Receives Grant to Advance its Pivotal Phase II Clinical Trial in Acute Coronary Syndrome

West Chester, May 8, 2007 - Molecular Targeting Technologies, Inc. announced today that it has been awarded a SBIR phase II grant from the National Heart Lung & Blood Institute (NHLBI). This grant will support a pivotal Phase II clinical trial to test the company's proprietary imaging agent to detect cardiac ischemia, or insufficient blood flow to the heart.

Professor Diwakar Jain, Professor of Medicine of Drexel University and Chair of the Tc-99m glucarate multi-center research study stated that "Triaging of the "chest pain" patient in the emergency room remains a real challenge for the physicians. In North America, over six million cases of chest pain and suspected acute myocardial infarction present to the emergency departments every year, of which approximately 20% are equivocal or difficult to triage. A test to rapidly detect those having acute myocardial infarction will allow us to select patients who need closer monitoring and intensive treatment. Currently, it takes over six billion dollars in healthcare costs and a prolonged time to rule in or rule out acute myocardial infarction in these patients. This research will evaluate whether Tc-99m glucarate imaging can provide a definitive answer in a shorter period of time, in the most complex group of patients."

Dr. Chris Pak, President and CEO of MTTI commented, "Tc-99m glucarate has the unique ability to distinguish the old from the new infarct. This multi-center trial is to evaluate patients who present with chest pain to the emergency room with suspected acute coronary syndrome but with no obvious signs of myocardial infarction. This study will determine the accuracy of diagnostic imaging of Tc-99m glucarate compared to standard clinical diagnostic procedures. We are extremely pleased to continue to receive funding from the NHLBI."

Professor Ban An Khaw of Northeastern University and co-founder of MTTI stated, "our previous findings indicated that Tc-99m glucarate localizes in acute non-reperfused and reperfused myocardial infarction with reperfused infarcts sequestering higher concentration of the reagent than non-reperfused MIs. Nonetheless, both types of MIs can be detected very early after the onset of chest pain by gamma imaging."

Molecular Targeting Technologies, Inc. (MTTI) is a privately held US based Biotechnology Company founded to develop novel medical imaging products for the diagnosis and treatment of cardiovascular disease and cancer. The company has since expanded its technology to include novel recombinant rabies vaccines for vaccination of

wildlife, human anti-rabies monoclonal antibodies for post-exposure prophylaxis, and a fusion protein technology for improved vaccines.

Contact: Jeffrey Mattis, PhD, [jmattis@mtarget.com](mailto:jmattis@mtarget.com), 610.738.7938